[Joint opinion of the German Society of Gastroenterology, Digestive and Metabolic Diseases (DGVS) and the German Society for Internal Medicine (DGIM) to Vedolizumab-benefit assessment according to § 35a SGB V the G-BA].
D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage* / Q000009:adverse effects*; D004334:Drug Administration Schedule; D005762:Gastroenterology / Q000592:standards*; D005765:Gastrointestinal Agents / Q000008:administration & dosage / Q000009:adverse effects; D005858:Germany; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy*; D017410:Practice Guidelines as Topic; D018570:Risk Assessment / Q000592:standards*
D061067:Antibodies, Monoclonal, Humanized; D005765:Gastrointestinal Agents; C543529:vedolizumab